Company / Shareholders' Equity
Anika Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$143.5M
FY2025
5-year range
$143.5M / $288.4M
FY2021-FY2025
Trend
-6.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 4 consecutive years, from $288M in FY2021 to $143M in FY2025.
Based on SEC 10-K filings.
$143M in FY2025 with a 5-year CAGR of -11.4%.
Declined from $212M to $143M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -19.2%
- 5-Year CAGR
- -11.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Anika Therapeutics, Inc.'s shareholders' equity has declined for 4 consecutive years.
- 5-year CAGR of -11.4%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 6.8% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $143.5M | -6.8% |
| FY2024 | $154.0M | -27.5% |
| FY2023 | $212.3M | -22.1% |
| FY2022 | $272.4M | -5.5% |
| FY2021 | $288.4M | +9.4% |
| FY2020 | $263.5M | +0.0% |
| FY2019 | $263.5M | +18.3% |
| FY2018 | $222.8M | +5.7% |
| FY2017 | $210.8M | +18.4% |
| FY2016 | $178.1M | +31.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026